ema prac naion semaglutide EMA's safety committee, the PRAC, has started a review of medicines containing following concerns regarding an increased risk of a non-arteritic anterior ischemic optic neuropathy… European Medicines Agency Investigating GLP-1

Methods like the IUD, implant, patch, ring, or injection are not affected by GLP-1s and are considered reliable

Key Takeaways No clinical trials have studied combining retatrutide and semaglutide: There is zero published human data on co-administration safety or efficacy Overlapping GLP-1 receptor activation creates compounding risk: Both compounds activate GLP-1 receptors, meaning combined use would double-stimulate the same pathway FDA labeling warns against GLP-1 agonist stacking: Approved GLP-1 drugs explicitly advise against co-administration with other GLP-1 receptor agonists Retatrutide already covers all three receptor pathways: As a triple agonist (GLP-1 + GIP + glucagon), adding semaglutide provides no additional receptor coverage Preclinical mouse data showed no added benefit: Combining retatrutide and semaglutide did not produce statistically different gastric emptying effects versus retatrutide alone Retatrutide is not yet FDA-approved: It remains investigational under Eli Lilly's TRIUMPH Phase 3 program with results expected through 2026 Why People Ask About Combining Retatrutide and Semaglutide The question of whether you can take retatrutide and semaglutide together comes up frequently in peptide research communities

Suitable for Training & Daily Use

Start: 200250 mcg daily